<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907500</url>
  </required_header>
  <id_info>
    <org_study_id>LISA 809 BER-401-20</org_study_id>
    <nct_id>NCT04907500</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of an Hydrophilic Acrylic Intraocular Lens</brief_title>
  <acronym>UVEA 809</acronym>
  <official_title>Prospective Evaluation of the Clinical Safety and Effectiveness of Hydrophilic Acrylic Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the clinical safety and effectiveness of an hydrophilic acrylic intraocular&#xD;
      lens&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To show safety and the effectiveness in regard to the monocular corrected distance visual&#xD;
      acuity (CDVA) and the distance-corrected near visual acuity (DCNVA) at 6 months&#xD;
      postoperative.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monocular corrected distance visual acuity (CDVA)</measure>
    <time_frame>6 months after the implantation</time_frame>
    <description>Monocular corrected distance visual acuity measured in logMAR</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Cataract Senile</condition>
  <arm_group>
    <arm_group_label>Multifocal IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of a multifocal intraocular lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraocular lens</intervention_name>
    <description>Cataract surgery</description>
    <arm_group_label>Multifocal IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of any gender, aged 18 years or older&#xD;
&#xD;
          2. Patient is planned for aged-related cataract surgery and implantation of the study IOL&#xD;
             into the capsular bag in at least one eye&#xD;
&#xD;
          3. Patient is willing and capable of providing informed consent&#xD;
&#xD;
          4. Patient is willing and capable of complying with visits and procedures as defined by&#xD;
             this protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Preoperative corrected distance visual acuity (CDVA) better than 0.3 logMAR (0.5&#xD;
             decimal)&#xD;
&#xD;
          2. Endothelial cell count of less than 2000/mm2&#xD;
&#xD;
          3. Ocular disorder that could potentially cause a clinically significant future visual&#xD;
             acuity loss&#xD;
&#xD;
          4. Preoperative corneal astigmatism ative corneal to be &lt; 1 D.&#xD;
&#xD;
          5. Clinically significant anterior segment pathology (e.g. chronic uveitis, iritis,&#xD;
             aniridia, rubeosis iridis, anterior membrane dystrophies, poor pupil dilation, etc.)&#xD;
&#xD;
          6. Clinically significant abnormal corneal finding (e.g. keratoconus, pellucid marginal&#xD;
             degeneration, or irregular astigmatism, clinically significant corneal membrane&#xD;
             dystrophies)&#xD;
&#xD;
          7. Any clinically significant condition that could affect IOL stability (e.g. zonular&#xD;
             dialysis, evident zonular weakness or dehiscence, etc.)&#xD;
&#xD;
          8. Any History of clinically significant retinal pathologies or ocular diagnosis (e.g.&#xD;
             diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment,&#xD;
             optic neuropathy optic nerve atrophy, amblyopia, strabismus, microphthalmos, aniridia,&#xD;
             epiretinal membrane etc.) that could alter or limit final postoperative visual&#xD;
             prognosis&#xD;
&#xD;
          9. Any acute infection (acute ocular disease, external/internal infection, systemic&#xD;
             infection)&#xD;
&#xD;
         10. Any previous intraocular and corneal surgery&#xD;
&#xD;
         11. Uncontrolled glaucoma or IOP higher than 24mmHg under ocular hypertension treatment&#xD;
&#xD;
         12. Current systemic or ocular pharmacotherapy that effects patients'vision&#xD;
&#xD;
         13. Current pathology or condition that could be a risk for the patient according to the&#xD;
             investigator opinion&#xD;
&#xD;
         14. Women during pregnancy and/or lactation&#xD;
&#xD;
         15. Patients unable to meet the limitations of the protocol or likely of noncooperation&#xD;
             during the trial&#xD;
&#xD;
         16. Patients whose freedom is impaired by administrative or legal order&#xD;
&#xD;
         17. Subject is enrolled in any other concurrent clinical study, with the exception of&#xD;
             local mandatory governmental registries and observational studies/registries, that do&#xD;
             not affect patients'vision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DUO STIL SRL , Clinica Oftalmologica Medoptic</name>
      <address>
        <city>Suceava</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anca Trifina, Dr</last_name>
      <phone>+40 723 999 800</phone>
    </contact>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

